Return to program book search
Dermatologic Drug Safety and Efficacy
Tuition fee and ticket required for admission
Friday, March 21
9:00 AM - 12:00 PM
Stephen E. Wolverton, MD, FAAD - Handout
- David R. Adams, MD, PharmD, FAAD - Handout
- James Q. Del Rosso, DO
- Kenneth B. Gordon, MD, FAAD
- Julie Claire Harper, MD, FAAD - Handout
- Junko Takeshita, MD, PhD, FAAD
Following this course, the attendee should be able to:
- Recognize the major risks that involve dermatologic drugs including drug interactions, cutaneous drug reactions and systemic adverse effects.
- Discuss whether drugs are truly efficacious for various dermatologic indications.
Clinicians in dermatology are continually challenged to make therapeutic decisions with less than ideal available scientific evidence. This session will focus both on drug safety (drug interactions, cutaneous drug reactions, and systemic adverse effects) and drug efficacy (determining the level of evidence for drug benefits for a given indication). The participants will gain significant educational tools to make wise clinical decisions, even when the literature is far from complete on drugs we utilize for dermatologic conditions, while maximizing both drug safety and efficacy.
- Wolverton SE (Ed). Comprehensive dermatologic drug therapy. (3rd ed.) Elsevier, London, 2012
|Friday, March 21|
|9:00 AM||Potentially significant risks of topical therapy: there is life beyond application site reactions / Dr. Del Rosso|
|9:25 AM||Drug interactions that are potentially life-threatening / Dr. Wolverton|
|9:50 AM||To prescribe or not to prescribe: evaluating the evidence for drug efficacy / Dr. Takeshita|
|10:15 AM||Putting drug risks into perspective: examples from isotretinoin therapy / Dr. Harper|
|10:40 AM||Adverse cutaneous drug reactions: some useful cases / Dr. Adams|
|11:05 AM||Clarifying the risks of biologic therapy in dermatology / Dr. Gordon|
|11:30 AM||Black box warnings: how to minimize the risk of these important complications / Dr. Wolverton|